The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
| Autor: | Chanida Vinayanuwatikun, Ploytuangporn Wongchanapai, Wilai Thawinwisan, Napa Parinyanitikun, Piyachut Chenaksara, Suebpong Tanasanvimon, Virote Sriuranpong, Siwat Sakdejayont, Nattaya Poovorawan, Pattama Angspatt, Shama Sukprakun, Veerisa Vimolchalao |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Olanzapine Adult Male medicine.medical_specialty Nausea Vomiting Antineoplastic Agents Placebo Gastroenterology Dexamethasone Ondansetron 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine medicine Humans Aged business.industry Hematology General Medicine Middle Aged Crossover study 030104 developmental biology Treatment Outcome Oncology 030220 oncology & carcinogenesis Antiemetics Surgery Female medicine.symptom business medicine.drug Chemotherapy-induced nausea and vomiting |
| Zdroj: | International journal of clinical oncology. 25(2) |
| ISSN: | 1437-7772 |
| Popis: | To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC). In this randomized, double-blind, placebo-controlled, crossover study, we randomly assigned chemotherapy-naive patients receiving HEC to receive olanzapine or placebo in addition to ondansetron and dexamethasone. All subjects were crossed over to another treatment arm on second-cycle chemotherapy. The primary endpoint was complete response (CR) rate defined as no vomiting and no use of rescue drugs. At the first cycle, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (68.7% vs. 25.0%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink